Related Experiment Video
Updated: May 8, 2026

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
The controversial role of microglia in malignant gliomas
Jun Wei1, Konrad Gabrusiewicz, Amy Heimberger
1Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-1402, USA.
Abstract:
Malignant gliomas contain stroma and a variety of immune cells including abundant activated microglia/macrophages. Mounting evidence indicates that the glioma microenvironment converts the glioma-associated microglia/macrophages (GAMs) into glioma-supportive, immunosuppressive cells; however, GAMs can retain intrinsic anti-tumor properties. Here, we review and discuss this duality and the potential therapeutic strategies that may inhibit their glioma-supportive and propagating functions.
Insights
Malignant gliomas involve immune cells like microglia/macrophages. These cells, known as glioma-associated microglia/macrophages (GAMs), can support tumors but also possess anti-tumor potential, offering therapeutic avenues.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Biology
Background:
- Malignant gliomas feature a complex tumor microenvironment.
- This microenvironment includes significant populations of microglia and macrophages.
Purpose of the Study:
- To review the dual role of glioma-associated microglia/macrophages (GAMs).
- To discuss therapeutic strategies targeting GAMs in malignant gliomas.
Main Methods:
- Literature review and synthesis of existing research.
- Analysis of the immunomodulatory functions of GAMs within the glioma microenvironment.
Main Results:
- Glioma-associated microglia/macrophages (GAMs) exhibit a dual nature.
- GAMs can be polarized towards immunosuppressive, tumor-promoting phenotypes.
- GAMs retain intrinsic anti-tumorigenic capabilities.
Conclusions:
- Understanding GAM duality is crucial for effective glioma treatment.
- Targeting GAMs offers potential therapeutic strategies to overcome immunosuppression and enhance anti-tumor immunity.

